<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30410033</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2056-676X</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>11</Month><Day>08</Day></PubDate></JournalIssue><Title>Nature reviews. Disease primers</Title><ISOAbbreviation>Nat Rev Dis Primers</ISOAbbreviation></Journal><ArticleTitle>Multiple sclerosis.</ArticleTitle><Pagination><MedlinePgn>43</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41572-018-0041-4</ELocationID><Abstract><AbstractText>Multiple sclerosis (MS) is the most common chronic inflammatory, demyelinating and neurodegenerative disease of the central nervous system in young adults. This disorder is a heterogeneous, multifactorial, immune-mediated disease that is influenced by both genetic and environmental factors. In most patients, reversible episodes of neurological dysfunction lasting several days or weeks characterize the initial stages of the disease (that is, clinically isolated syndrome and relapsing-remitting MS). Over time, irreversible clinical and cognitive deficits develop. A minority of patients have a progressive disease course from the onset. The pathological hallmark of MS is the formation of demyelinating lesions in the brain and spinal cord, which can be associated with neuro-axonal damage. Focal lesions are thought to be caused by the infiltration of immune cells, including T cells, B cells and myeloid cells, into the central nervous system parenchyma, with associated injury. MS is associated with a substantial burden on society owing to the high cost of the available treatments and poorer employment prospects and job retention for patients and their caregivers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Filippi</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy. filippi.massimo@hsr.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy. filippi.massimo@hsr.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bar-Or</LastName><ForeName>Amit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology and Center for Neuroinflammation and Experimental Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piehl</LastName><ForeName>Fredrik</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroimmunology Unit, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Preziosa</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solari</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Unit of Neuroepidemiology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vukusic</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Service de Neurologie, Sclérose en Plaques, Pathologies de la Myéline et Neuro-inflammation, Fondation Eugène Devic EDMUS Contre la Sclérose en Plaques, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rocca</LastName><ForeName>Maria A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>11</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Rev Dis Primers</MedlineTA><NlmUniqueID>101672103</NlmUniqueID><ISSNLinking>2056-676X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001384">Azetidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001593">Benzyl Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007189">Indans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010069">Oxadiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>5G7AKV2MKP</RegistryNumber><NameOfSubstance UI="C550169">ponesimod</NameOfSubstance></Chemical><Chemical><RegistryNumber>RR6P8L282I</RegistryNumber><NameOfSubstance UI="C578989">siponimod</NameOfSubstance></Chemical><Chemical><RegistryNumber>Z80293URPV</RegistryNumber><NameOfSubstance UI="C000607776">ozanimod</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Nat Rev Dis Primers. 2018 Nov 22;4(1):49</RefSource><PMID Version="1">30467372</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001384" MajorTopicYN="N">Azetidines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001593" MajorTopicYN="N">Benzyl Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003711" MajorTopicYN="N">Demyelinating Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007189" MajorTopicYN="N">Indans</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="N">Multiple Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010069" MajorTopicYN="N">Oxadiazoles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30410033</ArticleId><ArticleId IdType="doi">10.1038/s41572-018-0041-4</ArticleId><ArticleId IdType="pii">10.1038/s41572-018-0041-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lublin, F. D. et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83, 278–286 (2014). This is a proposal for a redefinition of MS clinical courses on the basis of the inclusion of disease activity (considering clinical relapse rate and imaging findings) and disease progression.</Citation><ArticleIdList><ArticleId IdType="pubmed">4117366</ArticleId><ArticleId IdType="pmcid">4117366</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000000560</ArticleId></ArticleIdList></Reference><Reference><Citation>Krieger, S. C., Cook, K., De Nino, S. &amp; Fletcher, M. The topographical model of multiple sclerosis: a dynamic visualization of disease course. Neurol. Neuroimmunol. Neuroinflamm. 3, e279 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27648465</ArticleId><ArticleId IdType="pmcid">5015541</ArticleId><ArticleId IdType="doi">10.1212/NXI.0000000000000279</ArticleId></ArticleIdList></Reference><Reference><Citation>Greer, J. M. &amp; McCombe, P. A. Role of gender in multiple sclerosis: clinical effects and potential molecular mechanisms. J. Neuroimmunol. 234, 7–18 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21474189</ArticleId><ArticleId IdType="doi">10.1016/j.jneuroim.2011.03.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeshokumar, A. K., Narula, S. &amp; Banwell, B. Pediatric multiple sclerosis. Curr. Opin. Neurol. 30, 216–221 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28323645</ArticleId><ArticleId IdType="doi">10.1097/WCO.0000000000000452</ArticleId></ArticleIdList></Reference><Reference><Citation>Multiple Sclerosis International Federation. Atlas of MS 2013: mapping multiple sclerosis around the world. MSIF.org https://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf (2013).</Citation></Reference><Reference><Citation>Gustavsson, A. et al. Cost of disorders of the brain in Europe 2010. Eur. Neuropsychopharmacol. 21, 718–779 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21924589</ArticleId><ArticleId IdType="doi">10.1016/j.euroneuro.2011.08.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, A. Y., Chonghasawat, A. O. &amp; Leadholm, K. L. Multiple sclerosis: frequency, cost, and economic burden in the United States. J. Clin. Neurosci. 45, 180–186 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28676312</ArticleId><ArticleId IdType="doi">10.1016/j.jocn.2017.06.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosati, G. The prevalence of multiple sclerosis in the world: an update. Neurol. Sci. 22, 117–139 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11603614</ArticleId><ArticleId IdType="doi">10.1007/s100720170011</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch-Henriksen, N. &amp; Sorensen, P. S. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol. 9, 520–532 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20398859</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(10)70064-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso, A. &amp; Hernan, M. A. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 71, 129–135 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18606967</ArticleId><ArticleId IdType="pmcid">4109189</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000316802.35974.34</ArticleId></ArticleIdList></Reference><Reference><Citation>Orton, S. M. et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol. 5, 932–936 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17052660</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(06)70581-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Scalfari, A. et al. Mortality in patients with multiple sclerosis. Neurology 81, 184–192 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23836941</ArticleId><ArticleId IdType="pmcid">3770174</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e31829a3388</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingwell, E. et al. Relative mortality and survival in multiple sclerosis: findings from British Columbia, Canada. J. Neurol. Neurosurg. Psychiatry 83, 61–66 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">21865212</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2011-300616</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunde, H. M. B., Assmus, J., Myhr, K. M., Bo, L. &amp; Grytten, N. Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study. J. Neurol. Neurosurg. Psychiatry 88, 621–625 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28365589</ArticleId><ArticleId IdType="pmcid">5537547</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2016-315238</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch-Henriksen, N., Laursen, B., Stenager, E. &amp; Magyari, M. Excess mortality among patients with multiple sclerosis in Denmark has dropped significantly over the past six decades: a population based study. J. Neurol. Neurosurg. Psychiatry 88, 626–631 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28705951</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2017-315907</ArticleId></ArticleIdList></Reference><Reference><Citation>Burkill, S. et al. Mortality trends for multiple sclerosis patients in Sweden from 1968 to 2012. Neurology 89, 555–562 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28687718</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000004216</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson, T., Barcellos, L. F. &amp; Alfredsson, L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat. Rev. Neurol. 13, 25–36 (2017). This comprehensive review summarizes recent findings on genetic, lifestyle and environmental risk factors for MS and their possible interactions.</Citation><ArticleIdList><ArticleId IdType="pubmed">27934854</ArticleId><ArticleId IdType="doi">10.1038/nrneurol.2016.187</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirzaei, F. et al. Gestational vitamin D and the risk of multiple sclerosis in offspring. Ann. Neurol. 70, 30–40 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21786297</ArticleId><ArticleId IdType="pmcid">3205990</ArticleId><ArticleId IdType="doi">10.1002/ana.22456</ArticleId></ArticleIdList></Reference><Reference><Citation>Endriz, J., Ho, P. P. &amp; Steinman, L. Time correlation between mononucleosis and initial symptoms of MS. Neurol. Neuroimmunol. Neuroinflamm. 4, e308 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28271078</ArticleId><ArticleId IdType="pmcid">5330199</ArticleId><ArticleId IdType="doi">10.1212/NXI.0000000000000308</ArticleId></ArticleIdList></Reference><Reference><Citation>Haahr, S., Plesner, A. M., Vestergaard, B. F. &amp; Hollsberg, P. A role of late Epstein-Barr virus infection in multiple sclerosis. Acta Neurol. Scand. 109, 270–275 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15016009</ArticleId><ArticleId IdType="doi">10.1046/j.1600-0404.2003.00221.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Healy, B. C. et al. Smoking and disease progression in multiple sclerosis. Arch. Neurol. 66, 858–864 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19597087</ArticleId><ArticleId IdType="pmcid">2754172</ArticleId><ArticleId IdType="doi">10.1001/archneurol.2009.122</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierrot-Deseilligny, C. &amp; Souberbielle, J. C. Vitamin D and multiple sclerosis: an update. Mult. Scler. Relat. Disord. 14, 35–45 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28619429</ArticleId><ArticleId IdType="doi">10.1016/j.msard.2017.03.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Harirchian, M. H., Fatehi, F., Sarraf, P., Honarvar, N. M. &amp; Bitarafan, S. Worldwide prevalence of familial multiple sclerosis: a systematic review and meta-analysis. Mult. Scler. Relat. Disord. 20, 43–47 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29291483</ArticleId><ArticleId IdType="doi">10.1016/j.msard.2017.12.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Compston, A. &amp; Coles, A. Multiple sclerosis. Lancet 359, 1221–1231 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11955556</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(02)08220-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Baranzini, S. E. &amp; Oksenberg, J. R. The genetics of multiple sclerosis: from 0 to 200 in 50 years. Trends Genet. 33, 960–970 (2017). This review presents a historical perspective on the progresses made in MS genetics and discusses the most recent findings, which have enabled the identification of&gt;200 loci that independently contribute to disease susceptibility and pathogenesis.</Citation><ArticleIdList><ArticleId IdType="pubmed">28987266</ArticleId><ArticleId IdType="doi">10.1016/j.tig.2017.09.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotsapas, C. &amp; Mitrovic, M. Genome-wide association studies of multiple sclerosis. Clin. Transl Immunol. 7, e1018 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cti2.1018</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jager, P. L. et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat. Genet. 41, 776–782 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19525953</ArticleId><ArticleId IdType="pmcid">2757648</ArticleId><ArticleId IdType="doi">10.1038/ng.401</ArticleId></ArticleIdList></Reference><Reference><Citation>International Multiple Sclerosis Genetics Consortium. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat. Genet. 45, 1353–1360 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2770</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedstrom, A. K. et al. Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis. Brain 134, 653–664 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21303861</ArticleId><ArticleId IdType="doi">10.1093/brain/awq371</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundqvist, E. et al. Epstein-Barr virus and multiple sclerosis: interaction with HLA. Genes Immun. 13, 14–20 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">21776012</ArticleId><ArticleId IdType="doi">10.1038/gene.2011.42</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedstrom, A. K. et al. Interaction between adolescent obesity and HLA risk genes in the etiology of multiple sclerosis. Neurology 82, 865–872 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24500647</ArticleId><ArticleId IdType="pmcid">3959752</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000000203</ArticleId></ArticleIdList></Reference><Reference><Citation>Mokry, L. E. et al. Vitamin D and risk of multiple sclerosis: a mendelian randomization study. PLOS Med. 12, e1001866 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26305103</ArticleId><ArticleId IdType="pmcid">4549308</ArticleId><ArticleId IdType="doi">10.1371/journal.pmed.1001866</ArticleId></ArticleIdList></Reference><Reference><Citation>Minagar, A. &amp; Alexander, J. S. Blood-brain barrier disruption in multiple sclerosis. Mult. Scler. 9, 540–549 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14664465</ArticleId><ArticleId IdType="doi">10.1191/1352458503ms965oa</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortiz, G. G. et al. Role of the blood-brain barrier in multiple sclerosis. Arch. Med. Res. 45, 687–697 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25431839</ArticleId><ArticleId IdType="doi">10.1016/j.arcmed.2014.11.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucchinetti, C. et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47, 707–717 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10852536</ArticleId><ArticleId IdType="doi">10.1002/1531-8249(200006)47:6&lt;707::AID-ANA3&gt;3.0.CO;2-Q</ArticleId></ArticleIdList></Reference><Reference><Citation>Frohman, E. M., Racke, M. K. &amp; Raine, C. S. Multiple sclerosis — the plaque and its pathogenesis. N. Engl. J. Med. 354, 942–955 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16510748</ArticleId><ArticleId IdType="doi">10.1056/NEJMra052130</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilmore, C. P. et al. Regional variations in the extent and pattern of grey matter demyelination in multiple sclerosis: a comparison between the cerebral cortex, cerebellar cortex, deep grey matter nuclei and the spinal cord. J. Neurol. Neurosurg. Psychiatry 80, 182–187 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">18829630</ArticleId><ArticleId IdType="doi">10.1136/jnnp.2008.148767</ArticleId></ArticleIdList></Reference><Reference><Citation>Green, A. J., McQuaid, S., Hauser, S. L., Allen, I. V. &amp; Lyness, R. Ocular pathology in multiple sclerosis: retinal atrophy and inflammation irrespective of disease duration. Brain 133, 1591–1601 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20410146</ArticleId><ArticleId IdType="pmcid">2877904</ArticleId><ArticleId IdType="doi">10.1093/brain/awq080</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrova, N., Carassiti, D., Altmann, D. R., Baker, D. &amp; Schmierer, K. Axonal loss in the multiple sclerosis spinal cord revisited. Brain Pathol. 28, 334–348 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28401686</ArticleId><ArticleId IdType="doi">10.1111/bpa.12516</ArticleId></ArticleIdList></Reference><Reference><Citation>Sormani, M. P., Rovaris, M., Comi, G. &amp; Filippi, M. A reassessment of the plateauing relationship between T2 lesion load and disability in MS. Neurology 73, 1538–1542 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19794123</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e3181c06679</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocca, M. A. et al. Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis. Lancet Neurol. 14, 302–317 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25662900</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(14)70250-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Frischer, J. M. et al. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann. Neurol. 78, 710–721 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26239536</ArticleId><ArticleId IdType="pmcid">4623970</ArticleId><ArticleId IdType="doi">10.1002/ana.24497</ArticleId></ArticleIdList></Reference><Reference><Citation>Machado-Santos, J. et al. The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+T lymphocytes and B cells. Brain 141, 2066–2082 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29873694</ArticleId><ArticleId IdType="pmcid">6022681</ArticleId><ArticleId IdType="doi">10.1093/brain/awy151</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassmann, H., van Horssen, J. &amp; Mahad, D. Progressive multiple sclerosis: pathology and pathogenesis. Nat. Rev. Neurol. 8, 647–656 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23007702</ArticleId><ArticleId IdType="doi">10.1038/nrneurol.2012.168</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahad, D. H., Trapp, B. D. &amp; Lassmann, H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 14, 183–193 (2015). This review discusses the complex immunological and neurodegenerative phenomena causing disease progression in patients with MS.</Citation><ArticleIdList><ArticleId IdType="pubmed">25772897</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(14)70256-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Prineas, J. W. et al. Immunopathology of secondary-progressive multiple sclerosis. Ann. Neurol. 50, 646–657 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11706971</ArticleId><ArticleId IdType="doi">10.1002/ana.1255</ArticleId></ArticleIdList></Reference><Reference><Citation>Dendrou, C. A., Fugger, L. &amp; Friese, M. A. Immunopathology of multiple sclerosis. Nat. Rev. Immunol. 15, 545–558 (2015). This comprehensive review summarizes the current understanding of MS immunopathology, focusing on the complex pathophysiological substrates involving both innate and adaptive immunity.</Citation><ArticleIdList><ArticleId IdType="pubmed">26250739</ArticleId><ArticleId IdType="doi">10.1038/nri3871</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassmann, H. Multiple sclerosis pathology. Cold Spring Harb. Perspect. Med. 8, a028936 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29358320</ArticleId><ArticleId IdType="doi">10.1101/cshperspect.a028936</ArticleId></ArticleIdList></Reference><Reference><Citation>Luchetti, S. et al. Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: a retrospective autopsy cohort analysis. Acta Neuropathol. 135, 511–528 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29441412</ArticleId><ArticleId IdType="pmcid">5978927</ArticleId><ArticleId IdType="doi">10.1007/s00401-018-1818-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutzelnigg, A. et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128, 2705–2712 (2005). By including pathological samples obtained from patients with MS with the main clinical phenotypes of the disease, this study shows that focal inflammation characterizes the earliest phases of MS, whereas diffuse inflammation, axonal loss and cortical demyelination occur in the progressive forms of the disease.</Citation><ArticleIdList><ArticleId IdType="pubmed">16230320</ArticleId><ArticleId IdType="doi">10.1093/brain/awh641</ArticleId></ArticleIdList></Reference><Reference><Citation>Evangelou, N., DeLuca, G. C., Owens, T. &amp; Esiri, M. M. Pathological study of spinal cord atrophy in multiple sclerosis suggests limited role of local lesions. Brain 128, 29–34 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15548559</ArticleId><ArticleId IdType="doi">10.1093/brain/awh323</ArticleId></ArticleIdList></Reference><Reference><Citation>Klaver, R., De Vries, H. E., Schenk, G. J. &amp; Geurts, J. J. Grey matter damage in multiple sclerosis: a pathology perspective. Prion 7, 66–75 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23324595</ArticleId><ArticleId IdType="pmcid">3609053</ArticleId><ArticleId IdType="doi">10.4161/pri.23499</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutzelnigg, A. et al. Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol. 17, 38–44 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17493036</ArticleId><ArticleId IdType="doi">10.1111/j.1750-3639.2006.00041.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Giorgio, A. et al. Cortical lesions in radiologically isolated syndrome. Neurology 77, 1896–1899 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22076541</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e318238ee9b</ArticleId></ArticleIdList></Reference><Reference><Citation>Filippi, M. et al. Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study. Lancet Neurol. 17, 133–142 (2018). This multicentre study compares the performance of the 2010 McDonald criteria and the 2016 Magnetic Resonance Imaging in MS (MAGNIMS) criteria for MS diagnosis in a large group of patients with CIS.</Citation><ArticleIdList><ArticleId IdType="pubmed">29275979</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(17)30469-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Haider, L. et al. Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron. J. Neurol. Neurosurg. Psychiatry 85, 1386–1395 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24899728</ArticleId><ArticleId IdType="pmcid">4251183</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2014-307712</ArticleId></ArticleIdList></Reference><Reference><Citation>Vercellino, M. et al. Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter. J. Neuropathol. Exp. Neurol. 68, 489–502 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19525897</ArticleId><ArticleId IdType="doi">10.1097/NEN.0b013e3181a19a5a</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi, S. R. et al. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain 135, 2925–2937 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22907116</ArticleId><ArticleId IdType="doi">10.1093/brain/aws189</ArticleId></ArticleIdList></Reference><Reference><Citation>Howell, O. W. et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 134, 2755–2771 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21840891</ArticleId><ArticleId IdType="doi">10.1093/brain/awr182</ArticleId></ArticleIdList></Reference><Reference><Citation>Magliozzi, R. et al. Inflammatory intrathecal profiles and cortical damage in multiple sclerosis. Ann. Neurol. 83, 739–755 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29518260</ArticleId><ArticleId IdType="doi">10.1002/ana.25197</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson, J. W., Bo, L., Mork, S., Chang, A. &amp; Trapp, B. D. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann. Neurol. 50, 389–400 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11558796</ArticleId><ArticleId IdType="doi">10.1002/ana.1123</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert, M., Antel, J., Bruck, W. &amp; Stadelmann, C. Extensive cortical remyelination in patients with chronic multiple sclerosis. Brain Pathol. 17, 129–138 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17388943</ArticleId><ArticleId IdType="doi">10.1111/j.1750-3639.2006.00043.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Strijbis, E. M. M., Kooi, E. J., van der Valk, P. &amp; Geurts, J. J. G. Cortical remyelination is heterogeneous in multiple sclerosis. J. Neuropathol. Exp. Neurol. 76, 390–401 (2017). This analysis of brain tissue sample from 21 chronic patients with MS shows more remyelination in the grey matter than in the white matter in the brains of patients with MS, with a trend towards more remyelination in patients with PPMS.</Citation><ArticleIdList><ArticleId IdType="pubmed">28521040</ArticleId><ArticleId IdType="doi">10.1093/jnen/nlx023</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutta, R. et al. Demyelination causes synaptic alterations in hippocampi from multiple sclerosis patients. Ann. Neurol. 69, 445–454 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21446020</ArticleId><ArticleId IdType="pmcid">3073544</ArticleId><ArticleId IdType="doi">10.1002/ana.22337</ArticleId></ArticleIdList></Reference><Reference><Citation>Jurgens, T. et al. Reconstruction of single cortical projection neurons reveals primary spine loss in multiple sclerosis. Brain 139, 39–46 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26667278</ArticleId><ArticleId IdType="doi">10.1093/brain/awv353</ArticleId></ArticleIdList></Reference><Reference><Citation>Bo, L., Vedeler, C. A., Nyland, H. I., Trapp, B. D. &amp; Mork, S. J. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J. Neuropathol. Exp. Neurol. 62, 723–732 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12901699</ArticleId><ArticleId IdType="doi">10.1093/jnen/62.7.723</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrikios, P. et al. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 129, 3165–3172 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16921173</ArticleId><ArticleId IdType="doi">10.1093/brain/awl217</ArticleId></ArticleIdList></Reference><Reference><Citation>Harlow, D. E., Honce, J. M. &amp; Miravalle, A. A. Remyelination therapy in multiple sclerosis. Front. Neurol. 6, 257 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26696956</ArticleId><ArticleId IdType="pmcid">4674562</ArticleId><ArticleId IdType="doi">10.3389/fneur.2015.00257</ArticleId></ArticleIdList></Reference><Reference><Citation>Prineas, J. W., Barnard, R. O., Kwon, E. E., Sharer, L. R. &amp; Cho, E. S. Multiple sclerosis: remyelination of nascent lesions. Ann. Neurol. 33, 137–151 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8434875</ArticleId><ArticleId IdType="doi">10.1002/ana.410330203</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklin, R. J. &amp; Ffrench-Constant, C. Remyelination in the CNS: from biology to therapy. Nat. Rev. Neurosci. 9, 839–855 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18931697</ArticleId><ArticleId IdType="doi">10.1038/nrn2480</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldschmidt, T., Antel, J., Konig, F. B., Bruck, W. &amp; Kuhlmann, T. Remyelination capacity of the MS brain decreases with disease chronicity. Neurology 72, 1914–1921 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19487649</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e3181a8260a</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, R., Patterson, K. &amp; Bar-Or, A. Reassessing the contributions of B cells in multiple sclerosis. Nat. Rev. Immunol. 19, 696–707 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-018-0135-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassmann, H. Targets of therapy in progressive MS. Mult. Scler. 23, 1593–1599 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29041864</ArticleId><ArticleId IdType="doi">10.1177/1352458517729455</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutta, R. &amp; Trapp, B. D. Relapsing and progressive forms of multiple sclerosis: insights from pathology. Curr. Opin. Neurol. 27, 271–278 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24722325</ArticleId><ArticleId IdType="pmcid">4132635</ArticleId><ArticleId IdType="doi">10.1097/WCO.0000000000000094</ArticleId></ArticleIdList></Reference><Reference><Citation>Baecher-Allan, C., Kaskow, B. J. &amp; Weiner, H. L. Multiple sclerosis: mechanisms and immunotherapy. Neuron 97, 742–768 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29470968</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2018.01.021</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaskow, B. J. &amp; Baecher-Allan, C. Effector T cells in multiple sclerosis. Cold Spring Harb. Perspect. Med. 8, a029025 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29358315</ArticleId><ArticleId IdType="doi">10.1101/cshperspect.a029025</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitz, A., Singer, E. &amp; Hafler, D. Regulatory T cells: from discovery to autoimmunity. Cold Spring Harb. Perspect. Med. https://doi.org/10.1101/cshperspect.a029041 (2018).</Citation></Reference><Reference><Citation>Viglietta, V., Baecher-Allan, C., Weiner, H. L. &amp; Hafler, D. A. Loss of functional suppression by CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199, 971–979 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15067033</ArticleId><ArticleId IdType="pmcid">2211881</ArticleId><ArticleId IdType="doi">10.1084/jem.20031579</ArticleId></ArticleIdList></Reference><Reference><Citation>Venken, K. et al. Compromised CD4<sup>+</sup> CD25<sup>high</sup> regulatory T cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. Immunology 123, 79–89 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">17897326</ArticleId><ArticleId IdType="pmcid">2433271</ArticleId><ArticleId IdType="doi">10.1111/j.1365-2567.2007.02690.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisullo, G. et al. Regulatory T cells fail to suppress CD4<sup>+</sup>T-bet<sup>+</sup> T cells in relapsing multiple sclerosis patients. Immunology 127, 418–428 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19016907</ArticleId><ArticleId IdType="pmcid">2712110</ArticleId><ArticleId IdType="doi">10.1111/j.1365-2567.2008.02963.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Astier, A. L., Meiffren, G., Freeman, S. &amp; Hafler, D. A. Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis. J. Clin. Invest. 116, 3252–3257 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17099776</ArticleId><ArticleId IdType="pmcid">1635165</ArticleId><ArticleId IdType="doi">10.1172/JCI29251</ArticleId></ArticleIdList></Reference><Reference><Citation>Fletcher, J. M. et al. CD39<sup>+</sup>Foxp3<sup>+</sup> regulatory T cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J. Immunol. 183, 7602–7610 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19917691</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.0901881</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhaeze, T. et al. Circulating follicular regulatory T cells are defective in multiple sclerosis. J. Immunol. 195, 832–840 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26071562</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.1500759</ArticleId></ArticleIdList></Reference><Reference><Citation>Kebir, H. et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat. Med. 13, 1173–1175 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17828272</ArticleId><ArticleId IdType="pmcid">5114125</ArticleId><ArticleId IdType="doi">10.1038/nm1651</ArticleId></ArticleIdList></Reference><Reference><Citation>Kebir, H. et al. Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis. Ann. Neurol. 66, 390–402 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19810097</ArticleId><ArticleId IdType="doi">10.1002/ana.21748</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber, M. et al. IL-17A secretion by CD8<sup>+</sup> T cells supports Th17-mediated autoimmune encephalomyelitis. J. Clin. Invest. 123, 247–260 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23221338</ArticleId><ArticleId IdType="doi">10.1172/JCI63681</ArticleId></ArticleIdList></Reference><Reference><Citation>van Langelaar, J. et al. T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early intervention. Brain 141, 1334–1349 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29659729</ArticleId><ArticleId IdType="doi">10.1093/brain/awy069</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasouli, J. et al. Expression of GM-CSF in T cells is increased in multiple sclerosis and suppressed by IFN-beta therapy. J. Immunol. 194, 5085–5093 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25917097</ArticleId><ArticleId IdType="pmcid">4433790</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.1403243</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahamsson, S. V. et al. Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis. Brain 136, 2888–2903 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23864273</ArticleId><ArticleId IdType="pmcid">3754461</ArticleId><ArticleId IdType="doi">10.1093/brain/awt182</ArticleId></ArticleIdList></Reference><Reference><Citation>Annibali, V. et al. CD161<sup>high</sup>CD8<sup>+</sup>T cells bear pathogenetic potential in multiple sclerosis. Brain 134, 542–554 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21216829</ArticleId><ArticleId IdType="doi">10.1093/brain/awq354</ArticleId></ArticleIdList></Reference><Reference><Citation>Jelcic, I. et al. Memory B cells activate brain-homing, autoreactive CD4<sup>+</sup> T cells in multiple sclerosis. Cell 175, 85–100 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30173916</ArticleId><ArticleId IdType="pmcid">6191934</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2018.08.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar-Or, A. The immunology of multiple sclerosis. Semin. Neurol. 28, 29–45 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18256985</ArticleId><ArticleId IdType="doi">10.1055/s-2007-1019124</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroenke, M. A., Carlson, T. J., Andjelkovic, A. V. &amp; Segal, B. M. IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J. Exp. Med. 205, 1535–1541 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18573909</ArticleId><ArticleId IdType="pmcid">2442630</ArticleId><ArticleId IdType="doi">10.1084/jem.20080159</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore, C. S. et al. miR-155 as a multiple sclerosis-relevant regulator of myeloid cell polarization. Ann. Neurol. 74, 709–720 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23818336</ArticleId><ArticleId IdType="doi">10.1002/ana.23967</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronchi, F. et al. Experimental priming of encephalitogenic Th1/Th17 cells requires pertussis toxin-driven IL-1beta production by myeloid cells. Nat. Commun. 7, 11541 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27189410</ArticleId><ArticleId IdType="pmcid">4873938</ArticleId><ArticleId IdType="doi">10.1038/ncomms11541</ArticleId></ArticleIdList></Reference><Reference><Citation>Louveau, A. et al. Structural and functional features of central nervous system lymphatic vessels. Nature 523, 337–341 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26030524</ArticleId><ArticleId IdType="pmcid">4506234</ArticleId><ArticleId IdType="doi">10.1038/nature14432</ArticleId></ArticleIdList></Reference><Reference><Citation>Palanichamy, A. et al. Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis. Sci. Transl Med. 6, 248ra106 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25100740</ArticleId><ArticleId IdType="pmcid">4176763</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.3008930</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern, J. N. et al. B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes. Sci. Transl Med. 6, 248ra107 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25100741</ArticleId><ArticleId IdType="pmcid">4388137</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.3008879</ArticleId></ArticleIdList></Reference><Reference><Citation>Larochelle, C. et al. Melanoma cell adhesion molecule-positive CD8 T lymphocytes mediate central nervous system inflammation. Ann. Neurol. 78, 39–53 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25869475</ArticleId><ArticleId IdType="doi">10.1002/ana.24415</ArticleId></ArticleIdList></Reference><Reference><Citation>Pare, A. et al. IL-1beta enables CNS access to CCR2<sup>hi</sup> monocytes and the generation of pathogenic cells through GM-CSF released by CNS endothelial cells. Proc. Natl Acad. Sci. USA 115, E1194–E1203 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29358392</ArticleId><ArticleId IdType="doi">10.1073/pnas.1714948115</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez, J. I. et al. JAML mediates monocyte and CD8 T cell migration across the brain endothelium. Ann. Clin. Transl Neurol. 2, 1032–1037 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26734656</ArticleId><ArticleId IdType="pmcid">4693623</ArticleId><ArticleId IdType="doi">10.1002/acn3.255</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Valk, P. &amp; Amor, S. Preactive lesions in multiple sclerosis. Curr. Opin. Neurol. 22, 207–213 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19417567</ArticleId><ArticleId IdType="doi">10.1097/WCO.0b013e32832b4c76</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez, J. I. et al. The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence. Science 334, 1727–1731 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22144466</ArticleId><ArticleId IdType="doi">10.1126/science.1206936</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez, J. I. et al. Focal disturbances in the blood-brain barrier are associated with formation of neuroinflammatory lesions. Neurobiol. Dis. 74, 14–24 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25448765</ArticleId><ArticleId IdType="doi">10.1016/j.nbd.2014.09.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Darlington, P. J. et al. Natural killer cells regulate Th17 cells after autologous hematopoietic stem cell transplantation for relapsing remitting multiple sclerosis. Front. Immunol. 9, 834 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29867923</ArticleId><ArticleId IdType="pmcid">5951114</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2018.00834</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold, R., Hartung, H. P. &amp; Lassmann, H. T cell apoptosis in autoimmune diseases: termination of inflammation in the nervous system and other sites with specialized immune-defense mechanisms. Trends Neurosci. 20, 399–404 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9292968</ArticleId><ArticleId IdType="doi">10.1016/S0166-2236(97)01079-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauser, S. L. et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N. Engl. J. Med. 376, 221–234 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28002679</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1601277</ArticleId></ArticleIdList></Reference><Reference><Citation>Palanichamy, A. et al. Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients. J. Immunol. 193, 580–586 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24928997</ArticleId><ArticleId IdType="pmcid">4082756</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.1400118</ArticleId></ArticleIdList></Reference><Reference><Citation>Cross, A. H., Stark, J. L., Lauber, J., Ramsbottom, M. J. &amp; Lyons, J. A. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J. Neuroimmunol. 180, 63–70 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16904756</ArticleId><ArticleId IdType="pmcid">1769354</ArticleId><ArticleId IdType="doi">10.1016/j.jneuroim.2006.06.029</ArticleId></ArticleIdList></Reference><Reference><Citation>Monson, N. L., Cravens, P. D., Frohman, E. M., Hawker, K. &amp; Racke, M. K. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch. Neurol. 62, 258–264 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15710854</ArticleId><ArticleId IdType="doi">10.1001/archneur.62.2.258</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar-Or, A. et al. Abnormal B cell cytokine responses a trigger of T cell-mediated disease in MS? Ann. Neurol. 67, 452–461 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20437580</ArticleId><ArticleId IdType="doi">10.1002/ana.21939</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, R. et al. Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy. Sci. Transl Med. 7, 310ra166 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26491076</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aab4176</ArticleId></ArticleIdList></Reference><Reference><Citation>Duddy, M. et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J. Immunol. 178, 6092–6099 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17475834</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.178.10.6092</ArticleId></ArticleIdList></Reference><Reference><Citation>Barr, T. A. et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J. Exp. Med. 209, 1001–1010 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22547654</ArticleId><ArticleId IdType="pmcid">3348102</ArticleId><ArticleId IdType="doi">10.1084/jem.20111675</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, R. et al. Cytokine-defined B cell responses as therapeutic targets in multiple sclerosis. Front. Immunol. 6, 626 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26779181</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2015.00170</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, R. et al. Antibody-independent function of human B cells contributes to antifungal T cell responses. J. Immunol. 198, 3245–3254 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28275140</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.1601572</ArticleId></ArticleIdList></Reference><Reference><Citation>Sergott, R. C. et al. ATON: results from a phase II randomized trial of the B cell-targeting agent atacicept in patients with optic neuritis. J. Neurol. Sci. 351, 174–178 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25758472</ArticleId><ArticleId IdType="doi">10.1016/j.jns.2015.02.019</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccio, L. et al. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch. Neurol. 67, 707–714 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20558389</ArticleId><ArticleId IdType="pmcid">2918395</ArticleId><ArticleId IdType="doi">10.1001/archneurol.2010.99</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava, R. et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N. Engl. J. Med. 367, 115–123 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22784115</ArticleId><ArticleId IdType="pmcid">5131800</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1110740</ArticleId></ArticleIdList></Reference><Reference><Citation>Brickshawana, A. et al. Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study. Lancet Neurol. 13, 795–806 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25008548</ArticleId><ArticleId IdType="pmcid">4144430</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(14)70141-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemmer, B. Antibodies to the inward rectifying potassium channel 4.1 in multiple sclerosis: different methodologies — conflicting results? Mult. Scler. 21, 537–539 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25583849</ArticleId><ArticleId IdType="doi">10.1177/1352458514564493</ArticleId></ArticleIdList></Reference><Reference><Citation>Narayan, R. et al. MOG antibody disease: a review of MOG antibody seropositive neuromyelitis optica spectrum disorder. Mult. Scler. Relat. Disord. 25, 66–72 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30048919</ArticleId><ArticleId IdType="doi">10.1016/j.msard.2018.07.025</ArticleId></ArticleIdList></Reference><Reference><Citation>Ketelslegers, I. A. et al. Anti-MOG antibodies plead against MS diagnosis in an Acquired Demyelinating Syndromes cohort. Mult. Scler. 21, 1513–1520 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25662345</ArticleId><ArticleId IdType="doi">10.1177/1352458514566666</ArticleId></ArticleIdList></Reference><Reference><Citation>Waters, P. et al. MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol. Neuroimmunol. Neuroinflamm. 2, e89 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25821844</ArticleId><ArticleId IdType="pmcid">4370386</ArticleId><ArticleId IdType="doi">10.1212/NXI.0000000000000089</ArticleId></ArticleIdList></Reference><Reference><Citation>Spadaro, M. et al. Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 3, e257 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27458601</ArticleId><ArticleId IdType="pmcid">4949775</ArticleId><ArticleId IdType="doi">10.1212/NXI.0000000000000257</ArticleId></ArticleIdList></Reference><Reference><Citation>Magliozzi, R. et al. A gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann. Neurol. 68, 477–493 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20976767</ArticleId><ArticleId IdType="doi">10.1002/ana.22230</ArticleId></ArticleIdList></Reference><Reference><Citation>Zrzavy, T. et al. Loss of ‘homeostatic’ microglia and patterns of their activation in active multiple sclerosis. Brain 140, 1900–1913 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28541408</ArticleId><ArticleId IdType="pmcid">6057548</ArticleId><ArticleId IdType="doi">10.1093/brain/awx113</ArticleId></ArticleIdList></Reference><Reference><Citation>Magliozzi, R. et al. B cell enrichment and Epstein-Barr virus infection in inflammatory cortical lesions in secondary progressive multiple sclerosis. J. Neuropathol. Exp. Neurol. 72, 29–41 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23242282</ArticleId><ArticleId IdType="doi">10.1097/NEN.0b013e31827bfc62</ArticleId></ArticleIdList></Reference><Reference><Citation>Lisak, R. P. et al. Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro. J. Neuroimmunol. 246, 85–95 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22458983</ArticleId><ArticleId IdType="doi">10.1016/j.jneuroim.2012.02.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Lisak, R. P. et al. B cells from patients with multiple sclerosis induce cell death via apoptosis in neurons in vitro. J. Neuroimmunol. 309, 88–99 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28601295</ArticleId><ArticleId IdType="doi">10.1016/j.jneuroim.2017.05.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Touil, H. et al. Human central nervous system astrocytes support survival and activation of B cells: implications for MS. J. Neuroinflammation 15, 114 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29673365</ArticleId><ArticleId IdType="pmcid">5907187</ArticleId><ArticleId IdType="doi">10.1186/s12974-018-1136-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller, D. H., Chard, D. T. &amp; Ciccarelli, O. Clinically isolated syndromes. Lancet Neurol. 11, 157–169 (2012). This review provides a summary of the main risk factors associated with a conversion to clinically definite MS and disability progression in patients with CIS.</Citation><ArticleIdList><ArticleId IdType="pubmed">22265211</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(11)70274-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Brownlee, W. J., Hardy, T. A., Fazekas, F. &amp; Miller, D. H. Diagnosis of multiple sclerosis: progress and challenges. Lancet 389, 1336–1346 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27889190</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(16)30959-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Toosy, A. T., Mason, D. F. &amp; Miller, D. H. Optic neuritis. Lancet Neurol. 13, 83–99 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24331795</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(13)70259-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Petzold, A. et al. The investigation of acute optic neuritis: a review and proposed protocol. Nat. Rev. Neurol. 10, 447–458 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25002105</ArticleId><ArticleId IdType="doi">10.1038/nrneurol.2014.108</ArticleId></ArticleIdList></Reference><Reference><Citation>Galetta, S. L. et al. Acute optic neuritis: unmet clinical needs and model for new therapies. Neurol. Neuroimmunol. Neuroinflamm. 2, e135 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26236761</ArticleId><ArticleId IdType="pmcid">4516397</ArticleId><ArticleId IdType="doi">10.1212/NXI.0000000000000135</ArticleId></ArticleIdList></Reference><Reference><Citation>Rae-Grant, A. D., Eckert, N. J., Bartz, S. &amp; Reed, J. F. Sensory symptoms of multiple sclerosis: a hidden reservoir of morbidity. Mult. Scler. 5, 179–183 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10408718</ArticleId><ArticleId IdType="doi">10.1177/135245859900500307</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanchandani, R. &amp; Howe, J. G. Lhermitte’s sign in multiple sclerosis: a clinical survey and review of the literature. J. Neurol. Neurosurg. Psychiatry 45, 308–312 (1982).</Citation><ArticleIdList><ArticleId IdType="pubmed">7077340</ArticleId><ArticleId IdType="pmcid">491365</ArticleId><ArticleId IdType="doi">10.1136/jnnp.45.4.308</ArticleId></ArticleIdList></Reference><Reference><Citation>McAlpine, D. in Multiple Sclerosis: A Reappraisal 2nd edn (eds McAlpine, D., Lumsden, C. E. &amp; Acheson, E. D.) 132–196 (Churchill Livingstone, 1972).</Citation></Reference><Reference><Citation>Dillon, B. E. &amp; Lemack, G. E. Urodynamics in the evaluation of the patient with multiple sclerosis: when are they helpful and how do we use them? Urol. Clin. North Am. 41, 439–444 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25063600</ArticleId><ArticleId IdType="doi">10.1016/j.ucl.2014.04.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Zipoli, V. et al. Cognitive impairment predicts conversion to multiple sclerosis in clinically isolated syndromes. Mult. Scler. 16, 62–67 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">19995837</ArticleId><ArticleId IdType="doi">10.1177/1352458509350311</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerdal, A., Celius, E. G., Krupp, L. &amp; Dahl, A. A. A prospective study of patterns of fatigue in multiple sclerosis. Eur. J. Neurol. 14, 1338–1343 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17903208</ArticleId><ArticleId IdType="doi">10.1111/j.1468-1331.2007.01974.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Filippi, M., Preziosa, P. &amp; Rocca, M. A. Brain mapping in multiple sclerosis: lessons learned about the human brain. Neuroimage https://doi.org/10.1016/j.neuroimage.2017.09.021 (2017).</Citation></Reference><Reference><Citation>Brass, S. D., Duquette, P., Proulx-Therrien, J. &amp; Auerbach, S. Sleep disorders in patients with multiple sclerosis. Sleep Med. Rev. 14, 121–129 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">19879170</ArticleId><ArticleId IdType="doi">10.1016/j.smrv.2009.07.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Veauthier, C. &amp; Paul, F. Sleep disorders in multiple sclerosis and their relationship to fatigue. Sleep Med. 15, 5–14 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24360534</ArticleId><ArticleId IdType="doi">10.1016/j.sleep.2013.08.791</ArticleId></ArticleIdList></Reference><Reference><Citation>Feinstein, A. Multiple sclerosis and depression. Mult. Scler. 17, 1276–1281 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22058085</ArticleId><ArticleId IdType="doi">10.1177/1352458511417835</ArticleId></ArticleIdList></Reference><Reference><Citation>Solaro, C. et al. The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. Neurology 63, 919–921 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15365151</ArticleId><ArticleId IdType="doi">10.1212/01.WNL.0000137047.85868.D6</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurtzke, J. F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33, 1444–1452 (1983).</Citation><ArticleIdList><ArticleId IdType="pubmed">6685237</ArticleId><ArticleId IdType="doi">10.1212/WNL.33.11.1444</ArticleId></ArticleIdList></Reference><Reference><Citation>Filippi, M. et al. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol. 15, 292–303 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26822746</ArticleId><ArticleId IdType="pmcid">4760851</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(15)00393-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Schumacher, F. Problems of experimental trials of therapy in multiple sclerosis. Ann. NY Acad. Sci. 122, 552–568 (1965).</Citation><ArticleIdList><ArticleId IdType="pubmed">14313512</ArticleId><ArticleId IdType="doi">10.1111/j.1749-6632.1965.tb20235.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Poser, C. M. et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13, 227–231 (1983).</Citation><ArticleIdList><ArticleId IdType="pubmed">6847134</ArticleId><ArticleId IdType="doi">10.1002/ana.410130302</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson, A. J. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 17, 162–173 (2018). This position paper presents an update to MS diagnostic criteria on the basis of a critical revision of new evidence and an expert opinion consensus from an international panel of experts.</Citation><ArticleIdList><ArticleId IdType="pubmed">29275977</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(17)30470-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobson, R., Ramagopalan, S., Davis, A. &amp; Giovannoni, G. Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. J. Neurol. Neurosurg. Psychiatry 84, 909–914 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23431079</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2012-304695</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrambide, G. et al. The value of oligoclonal bands in the multiple sclerosis diagnostic criteria. Brain 141, 1075–1084 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29462277</ArticleId><ArticleId IdType="doi">10.1093/brain/awy006</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhle, J. et al. Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study. Mult. Scler. 21, 1013–1024 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25680984</ArticleId><ArticleId IdType="doi">10.1177/1352458514568827</ArticleId></ArticleIdList></Reference><Reference><Citation>Leocani, L., Rocca, M. A. &amp; Comi, G. MRI and neurophysiological measures to predict course, disability and treatment response in multiple sclerosis. Curr. Opin. Neurol. 29, 243–253 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27058224</ArticleId><ArticleId IdType="doi">10.1097/WCO.0000000000000333</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald, W. I. et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50, 121–127 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11456302</ArticleId><ArticleId IdType="doi">10.1002/ana.1032</ArticleId></ArticleIdList></Reference><Reference><Citation>Polman, C. H. et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald criteria”. Ann. Neurol. 58, 840–846 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16283615</ArticleId><ArticleId IdType="doi">10.1002/ana.20703</ArticleId></ArticleIdList></Reference><Reference><Citation>Polman, C. H. et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 69, 292–302 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21387374</ArticleId><ArticleId IdType="pmcid">3084507</ArticleId><ArticleId IdType="doi">10.1002/ana.22366</ArticleId></ArticleIdList></Reference><Reference><Citation>van Waesberghe, J. H. et al. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann. Neurol. 46, 747–754 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10553992</ArticleId><ArticleId IdType="doi">10.1002/1531-8249(199911)46:5&lt;747::AID-ANA10&gt;3.0.CO;2-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovira, A. et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nat. Rev. Neurol. 11, 471–482 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26149978</ArticleId><ArticleId IdType="doi">10.1038/nrneurol.2015.106</ArticleId></ArticleIdList></Reference><Reference><Citation>De Stefano, N. et al. Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations. Mult. Scler. 24, 214–221 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29451440</ArticleId><ArticleId IdType="doi">10.1177/1352458517717808</ArticleId></ArticleIdList></Reference><Reference><Citation>Okuda, D. T. et al. Radiologically isolated syndrome: 5-year risk for an initial clinical event. PLOS ONE 9, e90509 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24598783</ArticleId><ArticleId IdType="pmcid">3943959</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0090509</ArticleId></ArticleIdList></Reference><Reference><Citation>Wattjes, M. P. et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis — establishing disease prognosis and monitoring patients. Nat. Rev. Neurol. 11, 597–606 (2015). This paper provides an evidence-based and expert opinion consensus of the MAGNIMS experts for the application of MRI in monitoring patients with MS and their treatments on the basis of a critical revision and discussion of state of the art MRI findings in these patients.</Citation><ArticleIdList><ArticleId IdType="pubmed">26369511</ArticleId></ArticleIdList></Reference><Reference><Citation>Brex, P. A. et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N. Engl. J. Med. 346, 158–164 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11796849</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa011341</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisniku, L. K. et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 131, 808–817 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18234696</ArticleId><ArticleId IdType="doi">10.1093/brain/awm329</ArticleId></ArticleIdList></Reference><Reference><Citation>Degenhardt, A., Ramagopalan, S. V., Scalfari, A. &amp; Ebers, G. C. Clinical prognostic factors in multiple sclerosis: a natural history review. Nat. Rev. Neurol. 5, 672–682 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19953117</ArticleId><ArticleId IdType="doi">10.1038/nrneurol.2009.178</ArticleId></ArticleIdList></Reference><Reference><Citation>Charil, A. et al. MRI and the diagnosis of multiple sclerosis: expanding the concept of “no better explanation”. Lancet Neurol. 5, 841–852 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16987731</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(06)70572-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Geraldes, R. et al. The current role of MRI in differentiating multiple sclerosis from its imaging mimics. Nat. Rev. Neurol. 14, 199–213 (2018). This review from MAGNIMS experts provides an update on the imaging characteristics that contribute to differentiate the most common mimics of MS, particularly age-related cerebrovascular disease and neuromyelitis optica.</Citation><ArticleIdList><ArticleId IdType="pubmed">29521337</ArticleId><ArticleId IdType="doi">10.1038/nrneurol.2018.14</ArticleId></ArticleIdList></Reference><Reference><Citation>Amato, M. P. et al. Environmental modifiable risk factors for multiple sclerosis: report from the 2016 ECTRIMS focused workshop. Mult. Scler. 24, 590–603 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458516686847</ArticleId></ArticleIdList></Reference><Reference><Citation>Sintzel, M. B., Rametta, M. &amp; Reder, A. T. Vitamin D and multiple sclerosis: a comprehensive review. Neurol. Ther. 7, 59–85 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29243029</ArticleId><ArticleId IdType="doi">10.1007/s40120-017-0086-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Granqvist, M. et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurol. 75, 320–327 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29309484</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2017.4011</ArticleId></ArticleIdList></Reference><Reference><Citation>Filippini, G. et al. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochrane Database Syst. Rev. 6, CD008933 (2013).</Citation></Reference><Reference><Citation>Okwuokenye, M., Zhang, A., Pace, A. &amp; Peace, K. E. Number needed to treat in multiple sclerosis clinical trials. Neurol. Ther. 6, 1–9 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28176189</ArticleId><ArticleId IdType="pmcid">5447556</ArticleId><ArticleId IdType="doi">10.1007/s40120-017-0063-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Montalban, X. et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult. Scler. 24, 96–120 (2018). This paper provides the guidelines proposed by the European Committee for Treatment and Research in MS and the European Academy of Neurology for the treatment of patients with MS.</Citation><ArticleIdList><ArticleId IdType="pubmed">29353550</ArticleId><ArticleId IdType="doi">10.1177/1352458517751049</ArticleId></ArticleIdList></Reference><Reference><Citation>Rae-Grant, A. et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis. Neurology 90, 777–788 (2018). This paper provides the guidelines proposed by the American Academy of Neurology for the treatment of patients with MS.</Citation><ArticleIdList><ArticleId IdType="pubmed">29686116</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000005347</ArticleId></ArticleIdList></Reference><Reference><Citation>Muraro, P. A. et al. Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis. JAMA Neurol. 74, 459–469 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28241268</ArticleId><ArticleId IdType="pmcid">5744858</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2016.5867</ArticleId></ArticleIdList></Reference><Reference><Citation>Sormani, M. P. et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a meta-analysis. Neurology 88, 2115–2122 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28455383</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000003987</ArticleId></ArticleIdList></Reference><Reference><Citation>Comi, G., Radaelli, M. &amp; Soelberg Sorensen, P. Evolving concepts in the treatment of relapsing multiple sclerosis. Lancet 389, 1347–1356 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27889192</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(16)32388-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Pakpoor, J. et al. No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurol. Neuroimmunol. Neuroinflamm. 2, e158 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26468472</ArticleId><ArticleId IdType="pmcid">4592538</ArticleId><ArticleId IdType="doi">10.1212/NXI.0000000000000158</ArticleId></ArticleIdList></Reference><Reference><Citation>Plavina, T. et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann. Neurol. 76, 802–812 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25273271</ArticleId><ArticleId IdType="doi">10.1002/ana.24286</ArticleId></ArticleIdList></Reference><Reference><Citation>Coles, A. J. et al. Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings. Neurology 89, 1117–1126 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28835403</ArticleId><ArticleId IdType="pmcid">5595276</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000004354</ArticleId></ArticleIdList></Reference><Reference><Citation>Havrdova, E. et al. Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy. Neurology 89, 1107–1116 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28835401</ArticleId><ArticleId IdType="pmcid">5595278</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000004313</ArticleId></ArticleIdList></Reference><Reference><Citation>Piehl, F. A changing treatment landscape for multiple sclerosis: challenges and opportunities. J. Intern. Med. 275, 364–381 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24444084</ArticleId><ArticleId IdType="doi">10.1111/joim.12204</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartung, H. P. et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360, 2018–2025 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12504397</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(02)12023-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Lublin, F. et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 387, 1075–1084 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26827074</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(15)01314-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapoor, R. et al. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol. 17, 405–415 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29545067</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(18)30069-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawker, K. et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann. Neurol. 66, 460–471 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19847908</ArticleId><ArticleId IdType="doi">10.1002/ana.21867</ArticleId></ArticleIdList></Reference><Reference><Citation>Montalban, X. et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N. Engl. J. Med. 376, 209–220 (2017). This 2-year phase III randomized clinical trial shows that in patients with primary progressive MS, compared with placebo, ocrelizumab reduces focal lesion accumulation, brain volume loss and disability progression.</Citation><ArticleIdList><ArticleId IdType="pubmed">28002688</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1606468</ArticleId></ArticleIdList></Reference><Reference><Citation>Amtmann, D., Bamer, A. M., Kim, J., Chung, H. &amp; Salem, R. People with multiple sclerosis report significantly worse symptoms and health related quality of life than the US general population as measured by PROMIS and NeuroQoL outcome measures. Disabil. Health J. 11, 99–107 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">28442320</ArticleId><ArticleId IdType="doi">10.1016/j.dhjo.2017.04.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovannoni, G. et al. Brain health: time matters in multiple sclerosis. Mult. Scler. Relat. Disord. 9, S5–S48 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27640924</ArticleId><ArticleId IdType="doi">10.1016/j.msard.2016.07.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Collin, C. et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol. Res. 32, 451–459 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20307378</ArticleId><ArticleId IdType="doi">10.1179/016164109X12590518685660</ArticleId></ArticleIdList></Reference><Reference><Citation>Novotna, A. et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur. J. Neurol. 18, 1122–1131 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21362108</ArticleId><ArticleId IdType="doi">10.1111/j.1468-1331.2010.03328.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodman, A. D. et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann. Neurol. 68, 494–502 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20976768</ArticleId><ArticleId IdType="doi">10.1002/ana.22240</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodman, A. D. et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 373, 732–738 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19249634</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(09)60442-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Moulin, D. et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res. Manag. 19, 328–335 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25479151</ArticleId><ArticleId IdType="pmcid">4273712</ArticleId><ArticleId IdType="doi">10.1155/2014/754693</ArticleId></ArticleIdList></Reference><Reference><Citation>Aharony, S. M., Lam, O. &amp; Corcos, J. Treatment of lower urinary tract symptoms in multiple sclerosis patients: review of the literature and current guidelines. Can. Urol. Assoc. J. 11, E110–E115 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28360957</ArticleId><ArticleId IdType="pmcid">5365386</ArticleId><ArticleId IdType="doi">10.5489/cuaj.4059</ArticleId></ArticleIdList></Reference><Reference><Citation>Amato, M. P. et al. Treatment of cognitive impairment in multiple sclerosis: position paper. J. Neurol. 260, 1452–1468 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23180174</ArticleId><ArticleId IdType="doi">10.1007/s00415-012-6678-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobelt, G. et al. New insights into the burden and costs of multiple sclerosis in Europe. Mult. Scler. 23, 1123–1136 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28273775</ArticleId><ArticleId IdType="pmcid">5476197</ArticleId><ArticleId IdType="doi">10.1177/1352458517694432</ArticleId></ArticleIdList></Reference><Reference><Citation>Marrie, R. A. et al. The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review. Mult. Scler. 21, 305–317 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25583845</ArticleId><ArticleId IdType="pmcid">4429164</ArticleId><ArticleId IdType="doi">10.1177/1352458514564487</ArticleId></ArticleIdList></Reference><Reference><Citation>Stankoff, B. et al. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology 64, 1139–1143 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15824337</ArticleId><ArticleId IdType="doi">10.1212/01.WNL.0000158272.27070.6A</ArticleId></ArticleIdList></Reference><Reference><Citation>Asano, M. &amp; Finlayson, M. L. Meta-analysis of three different types of fatigue management interventions for people with multiple sclerosis: exercise, education, and medication. Mult. Scler. Int. 2014, 798285 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24963407</ArticleId><ArticleId IdType="pmcid">4052049</ArticleId></ArticleIdList></Reference><Reference><Citation>Achiron, A. et al. Effect of alfacalcidol on multiple sclerosis-related fatigue: a randomized, double-blind placebo-controlled study. Mult. Scler. 21, 767–775 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25344375</ArticleId><ArticleId IdType="doi">10.1177/1352458514554053</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottgen, J. et al. Randomised controlled trial of a self-guided online fatigue intervention in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 89, 970–976 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29549193</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2017-317463</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaede, G. et al. Safety and preliminary efficacy of deep transcranial magnetic stimulation in MS-related fatigue. Neurol. Neuroimmunol. Neuroinflamm. 5, e423 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29259998</ArticleId><ArticleId IdType="doi">10.1212/NXI.0000000000000423</ArticleId></ArticleIdList></Reference><Reference><Citation>Veauthier, C., Hasselmann, H., Gold, S. M. &amp; Paul, F. The Berlin Treatment Algorithm: recommendations for tailored innovative therapeutic strategies for multiple sclerosis-related fatigue. EPMA J. 7, 25 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27904656</ArticleId><ArticleId IdType="pmcid">5121967</ArticleId><ArticleId IdType="doi">10.1186/s13167-016-0073-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiest, K. M. et al. Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis. Mult. Scler. Relat. Disord. 5, 12–26 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26856938</ArticleId><ArticleId IdType="doi">10.1016/j.msard.2015.10.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner, P. &amp; Piehl, F. Fatigue and depression in multiple sclerosis: pharmacological and non-pharmacological interventions. Acta Neurol. Scand. 134, S47–S54 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ane.12648</ArticleId></ArticleIdList></Reference><Reference><Citation>Motl, R. W. et al. Exercise in patients with multiple sclerosis. Lancet Neurol. 16, 848–856 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28920890</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(17)30281-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Sormani, M. P. &amp; Bruzzi, P. MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials. Lancet Neurol. 12, 669–676 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23743084</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(13)70103-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Pullicino, R., Radon, M., Biswas, S., Bhojak, M. &amp; Das, K. A. Review of the current evidence on gadolinium deposition in the brain. Clin. Neuroradiol 28, 159–169 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29523896</ArticleId><ArticleId IdType="doi">10.1007/s00062-018-0678-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Filippi, M. et al. Gray matter damage predicts the accumulation of disability 13 years later in MS. Neurology 81, 1759–1767 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24122185</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000435551.90824.d0</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocca, M. A. et al. Brain MRI atrophy quantification in MS: from methods to clinical application. Neurology 88, 403–413 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27986875</ArticleId><ArticleId IdType="pmcid">5272969</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000003542</ArticleId></ArticleIdList></Reference><Reference><Citation>Sormani, M. P., Arnold, D. L. &amp; De Stefano, N. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann. Neurol. 75, 43–49 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24006277</ArticleId><ArticleId IdType="doi">10.1002/ana.24018</ArticleId></ArticleIdList></Reference><Reference><Citation>Comabella, M. &amp; Montalban, X. Body fluid biomarkers in multiple sclerosis. Lancet Neurol. 13, 113–126 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24331797</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(13)70233-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Kappos, L. et al. Safety and efficacy of siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis: dose-blinded, randomized extension of the phase 2 BOLD study. JAMA Neurol. 73, 1089–1098 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27380540</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2016.1451</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen, J. A. et al. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 15, 373–381 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26879276</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(16)00018-1</ArticleId></ArticleIdList></Reference><Reference><Citation>van Noort, J. M., Bsibsi, M., Nacken, P. J., Verbeek, R. &amp; Venneker, E. H. Therapeutic intervention in multiple sclerosis with alpha B-crystallin: a randomized controlled phase IIa trial. PLOS ONE 10, e0143366 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26599332</ArticleId><ArticleId IdType="pmcid">4657879</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0143366</ArticleId></ArticleIdList></Reference><Reference><Citation>Walczak, A., Siger, M., Ciach, A., Szczepanik, M. &amp; Selmaj, K. Transdermal application of myelin peptides in multiple sclerosis treatment. JAMA Neurol. 70, 1105–1109 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23817921</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2013.3022</ArticleId></ArticleIdList></Reference><Reference><Citation>Raftopoulos, R. et al. Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 15, 259–269 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26822749</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(16)00004-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Green, A. J. et al. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Lancet 390, 2481–2489 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29029896</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(17)32346-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Chataway, J. et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet 383, 2213–2221 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24655729</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(13)62242-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran, J. Q. et al. Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033. Neurol. Neuroimmunol. Neuroinflamm. 1, e18 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25340070</ArticleId><ArticleId IdType="pmcid">4202679</ArticleId><ArticleId IdType="doi">10.1212/NXI.0000000000000018</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranger, A. et al. Anti-LINGO-1 has no detectable immunomodulatory effects in preclinical and phase 1 studies. Neurol. Neuroimmunol. Neuroinflamm. 5, e417 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29259995</ArticleId><ArticleId IdType="doi">10.1212/NXI.0000000000000417</ArticleId></ArticleIdList></Reference><Reference><Citation>Mische, L. J. &amp; Mowry, E. M. The evidence for dietary interventions and nutritional supplements as treatment options in multiple sclerosis: a review. Curr. Treat. Options Neurol. 20, 8 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29549521</ArticleId><ArticleId IdType="doi">10.1007/s11940-018-0494-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell, A. J., Benito-Leon, J., Gonzalez, J. M. &amp; Rivera-Navarro, J. Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing. Lancet Neurol. 4, 556–566 (2005). This review summarizes the clinical relevance of health-related quality of life assessment in patients with MS, focusing on its practical measurement and its interplay with psychosocial and emotional domains.</Citation><ArticleIdList><ArticleId IdType="pubmed">16109362</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(05)70166-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Solari, A. Role of health-related quality of life measures in the routine care of people with multiple sclerosis. Health Qual. Life Outcomes 3, 16 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15777478</ArticleId><ArticleId IdType="pmcid">555749</ArticleId><ArticleId IdType="doi">10.1186/1477-7525-3-16</ArticleId></ArticleIdList></Reference><Reference><Citation>US Department of Health and Human Services. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. FDA.gov https://www.fda.gov/downloads/drugs/guidances/ucm193282.pdf (2009).</Citation></Reference><Reference><Citation>Committee For Medicinal Products For Human Use. Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. EMA.europa.eu https://www.ema.europa.eu/regulatory-guidance-use-health-related-quality-life-hrql-measures-evaluation-medicinal-products (2005).</Citation></Reference><Reference><Citation>Vickrey, B. G., Hays, R. D., Harooni, R., Myers, L. W. &amp; Ellison, G. W. A health-related quality of life measure for multiple sclerosis. Qual. Life Res. 4, 187–206 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7613530</ArticleId><ArticleId IdType="doi">10.1007/BF02260859</ArticleId></ArticleIdList></Reference><Reference><Citation>Cella, D. F. et al. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 47, 129–139 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8710066</ArticleId><ArticleId IdType="doi">10.1212/WNL.47.1.129</ArticleId></ArticleIdList></Reference><Reference><Citation>Bond, T. G. &amp; Fox, C. M. Applying the Rasch Model: Fundamental Measurement in the Human Sciences 2nd edn (Routledge, 2007).</Citation></Reference><Reference><Citation>Ford, H. L. et al. Developing a disease-specific quality of life measure for people with multiple sclerosis. Clin. Rehabil. 15, 247–258 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11386394</ArticleId><ArticleId IdType="doi">10.1191/026921501673658108</ArticleId></ArticleIdList></Reference><Reference><Citation>Doward, L. C., McKenna, S. P., Meads, D. M., Twiss, J. &amp; Eckert, B. J. The development of patient-reported outcome indices for multiple sclerosis (PRIMUS). Mult. Scler. 15, 1092–1102 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19556315</ArticleId><ArticleId IdType="doi">10.1177/1352458509106513</ArticleId></ArticleIdList></Reference><Reference><Citation>Simeoni, M. et al. Validation of the Multiple Sclerosis International Quality of Life questionnaire. Mult. Scler. 14, 219–230 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">17942521</ArticleId><ArticleId IdType="doi">10.1177/1352458507080733</ArticleId></ArticleIdList></Reference><Reference><Citation>Giordano, A. et al. Responsiveness of patient reported outcome measures in multiple sclerosis relapses: the REMS study. J. Neurol. Neurosurg. Psychiatry 80, 1023–1028 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19443471</ArticleId><ArticleId IdType="doi">10.1136/jnnp.2008.171181</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold, S. M. et al. Responsiveness of patient-based and external rating scales in multiple sclerosis: head-to-head comparison in three clinical settings. J. Neurol. Sci. 290, 102–106 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">19922955</ArticleId><ArticleId IdType="doi">10.1016/j.jns.2009.10.020</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore, F., Vickrey, B., Fortin, K. &amp; Lee, L. Two multiple sclerosis quality-of-life measures: comparison in a national sample. Can. J. Neurol. Sci. 42, 55–63 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25586701</ArticleId><ArticleId IdType="doi">10.1017/cjn.2014.128</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosato, R. et al. Development of a short version of MSQOL-54 using factor analysis and item response theory. PLOS ONE 11, e0153466 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27078146</ArticleId><ArticleId IdType="pmcid">4831784</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0153466</ArticleId></ArticleIdList></Reference><Reference><Citation>Twiss, J., Doward, L. C., McKenna, S. P. &amp; Eckert, B. Interpreting scores on multiple sclerosis-specific patient reported outcome measures (the PRIMUS and U-FIS). Health Qual. Life Outcomes 8, 117 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20937112</ArticleId><ArticleId IdType="pmcid">2964544</ArticleId><ArticleId IdType="doi">10.1186/1477-7525-8-117</ArticleId></ArticleIdList></Reference><Reference><Citation>Reeve, B. B. et al. Psychometric evaluation and calibration of health-related quality of life item banks: plans for the patient-reported outcomes measurement information system (PROMIS). Med. Care 45, S22–S31 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17443115</ArticleId><ArticleId IdType="doi">10.1097/01.mlr.0000250483.85507.04</ArticleId></ArticleIdList></Reference><Reference><Citation>Michel, P. et al. A multidimensional computerized adaptive short-form quality of life questionnaire developed and validated for multiple sclerosis: the MusiQoL-MCAT. Medicine 95, e3068 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27057832</ArticleId><ArticleId IdType="pmcid">4998748</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000003068</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon, A. J. et al. The contemporary spectrum of multiple sclerosis misdiagnosis: a multicenter study. Neurology 87, 1393–1399 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27581217</ArticleId><ArticleId IdType="pmcid">5047038</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000003152</ArticleId></ArticleIdList></Reference><Reference><Citation>Sati, P. et al. The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. Nat. Rev. Neurol. 12, 714–722 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27834394</ArticleId><ArticleId IdType="doi">10.1038/nrneurol.2016.166</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinnecker, T. et al. Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis. Neurology 79, 708–714 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22855861</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e3182648bc8</ArticleId></ArticleIdList></Reference><Reference><Citation>Maggi, P. et al. Central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies. Ann. Neurol. 83, 283–294 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29328521</ArticleId><ArticleId IdType="pmcid">5901412</ArticleId><ArticleId IdType="doi">10.1002/ana.25146</ArticleId></ArticleIdList></Reference><Reference><Citation>Mistry, N. et al. Imaging central veins in brain lesions with 3-T T2*-weighted magnetic resonance imaging differentiates multiple sclerosis from microangiopathic brain lesions. Mult. Scler. 22, 1289–1296 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26658816</ArticleId><ArticleId IdType="doi">10.1177/1352458515616700</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon, A. J. et al. Diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm. Mult. Scler. 24, 750–757 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28820013</ArticleId><ArticleId IdType="doi">10.1177/1352458517726383</ArticleId></ArticleIdList></Reference><Reference><Citation>Norgren, N., Rosengren, L. &amp; Stigbrand, T. Elevated neurofilament levels in neurological diseases. Brain Res. 987, 25–31 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14499942</ArticleId><ArticleId IdType="doi">10.1016/S0006-8993(03)03219-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Teunissen, C. E., Malekzadeh, A., Leurs, C., Bridel, C. &amp; Killestein, J. Body fluid biomarkers for multiple sclerosis—the long road to clinical application. Nat. Rev. Neurol. 11, 585–596 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26392381</ArticleId><ArticleId IdType="doi">10.1038/nrneurol.2015.173</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrambide, G. et al. Neurofilament light chain level is a weak risk factor for the development of MS. Neurology 87, 1076–1084 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27521440</ArticleId><ArticleId IdType="pmcid">5027802</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000003085</ArticleId></ArticleIdList></Reference><Reference><Citation>Matute-Blanch, C. et al. Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. Brain 141, 1085–1093 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29452342</ArticleId><ArticleId IdType="doi">10.1093/brain/awy021</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil, M. et al. CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome. Mult. Scler. 19, 436–442 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">22917689</ArticleId><ArticleId IdType="pmcid">3652709</ArticleId><ArticleId IdType="doi">10.1177/1352458512458010</ArticleId></ArticleIdList></Reference><Reference><Citation>Disanto, G. et al. Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann. Neurol. 81, 857–870 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28512753</ArticleId><ArticleId IdType="pmcid">5519945</ArticleId><ArticleId IdType="doi">10.1002/ana.24954</ArticleId></ArticleIdList></Reference><Reference><Citation>Disanto, G. et al. Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. J. Neurol. Neurosurg. Psychiatry 87, 126–129 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">25716934</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2016-315106.121</ArticleId></ArticleIdList></Reference><Reference><Citation>Siller, N. et al. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis. Mult. Scler. https://doi.org/10.1177/1352458518765666 (2018).</Citation></Reference><Reference><Citation>Petzold, A., Steenwijk, M. D., Eikelenboom, J. M., Wattjes, M. P. &amp; Uitdehaag, B. M. Elevated CSF neurofilament proteins predict brain atrophy: a 15-year follow-up study. Mult. Scler. 22, 1154–1162 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27207456</ArticleId><ArticleId IdType="doi">10.1177/1352458516645206</ArticleId></ArticleIdList></Reference><Reference><Citation>Salzer, J., Svenningsson, A. &amp; Sundstrom, P. Neurofilament light as a prognostic marker in multiple sclerosis. Mult. Scler. 16, 287–292 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20086018</ArticleId><ArticleId IdType="doi">10.1177/1352458509359725</ArticleId></ArticleIdList></Reference><Reference><Citation>Trentini, A. et al. N-acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis. J. Neurol. 261, 2338–2343 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25228004</ArticleId><ArticleId IdType="doi">10.1007/s00415-014-7507-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunnarsson, M. et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann. Neurol. 69, 83–89 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21280078</ArticleId><ArticleId IdType="doi">10.1002/ana.22247</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhle, J. et al. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology 84, 1639–1643 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25809304</ArticleId><ArticleId IdType="pmcid">4409586</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000001491</ArticleId></ArticleIdList></Reference><Reference><Citation>Piehl, F. et al. Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod. Mult. Scler. 24, 1046–1054 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28627962</ArticleId><ArticleId IdType="doi">10.1177/1352458517715132</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberwahrenbrock, T. et al. Multicenter reliability of semiautomatic retinal layer segmentation using OCT. Neurol. Neuroimmunol. Neuroinflamm. 5, e449 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29552598</ArticleId><ArticleId IdType="pmcid">5852947</ArticleId><ArticleId IdType="doi">10.1212/NXI.0000000000000449</ArticleId></ArticleIdList></Reference><Reference><Citation>Schippling, S. et al. Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria. Mult. Scler. 21, 163–170 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">24948688</ArticleId><ArticleId IdType="doi">10.1177/1352458514538110</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz-Herranz, A. et al. The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. Neurology 86, 2303–2309 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27225223</ArticleId><ArticleId IdType="pmcid">4909557</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000002774</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann, H. G. et al. Association of retinal ganglion cell layer thickness with future disease activity in patients with clinically isolated syndrome. JAMA Neurol. 75, 1071–1079 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29710121</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2018.1011</ArticleId></ArticleIdList></Reference><Reference><Citation>Costello, F. et al. Tracking retinal nerve fiber layer loss after optic neuritis: a prospective study using optical coherence tomography. Mult. Scler. 14, 893–905 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18573837</ArticleId><ArticleId IdType="doi">10.1177/1352458508091367</ArticleId></ArticleIdList></Reference><Reference><Citation>Petzold, A. et al. Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol. 9, 921–932 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20723847</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(10)70168-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Petzold, A. et al. Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol. 16, 797–812 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28920886</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(17)30278-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabilondo, I. et al. Dynamics of retinal injury after acute optic neuritis. Ann. Neurol. 77, 517–528 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25559267</ArticleId><ArticleId IdType="doi">10.1002/ana.24351</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberwahrenbrock, T. et al. Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome. Mult. Scler. 19, 1887–1895 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23702433</ArticleId><ArticleId IdType="doi">10.1177/1352458513489757</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulicken, M. et al. Optical coherence tomography and disease subtype in multiple sclerosis. Neurology 69, 2085–2092 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">18040015</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000294876.49861.dc</ArticleId></ArticleIdList></Reference><Reference><Citation>Narayanan, D. et al. Tracking changes over time in retinal nerve fiber layer and ganglion cell-inner plexiform layer thickness in multiple sclerosis. Mult. Scler. 20, 1331–1341 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24639478</ArticleId><ArticleId IdType="pmcid">4306466</ArticleId><ArticleId IdType="doi">10.1177/1352458514523498</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambe, J., Murphy, O. C. &amp; Saidha, S. Can optical coherence tomography be used to guide treatment decisions in adult or pediatric multiple sclerosis? Curr. Treat. Options Neurol. 20, 9 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29564662</ArticleId><ArticleId IdType="doi">10.1007/s11940-018-0493-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon-Lipkin, E. et al. Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology 69, 1603–1609 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17938370</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000295995.46586.ae</ArticleId></ArticleIdList></Reference><Reference><Citation>Saidha, S. et al. Relationships between retinal axonal and neuronal measures and global central nervous system pathology in multiple sclerosis. JAMA Neurol. 70, 34–43 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23318513</ArticleId><ArticleId IdType="pmcid">4030557</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2013.573</ArticleId></ArticleIdList></Reference><Reference><Citation>Balcer, L. J., Miller, D. H., Reingold, S. C. &amp; Cohen, J. A. Vision and vision-related outcome measures in multiple sclerosis. Brain 138, 11–27 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25433914</ArticleId><ArticleId IdType="doi">10.1093/brain/awu335</ArticleId></ArticleIdList></Reference><Reference><Citation>Seewann, A. et al. Postmortem verification of MS cortical lesion detection with 3D DIR. Neurology 78, 302–308 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22218278</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e31824528a0</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabrese, M. et al. No MRI evidence of cortical lesions in neuromyelitis optica. Neurology 79, 1671–1676 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22993282</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e31826e9a96</ArticleId></ArticleIdList></Reference><Reference><Citation>Absinta, M. et al. Patients with migraine do not have MRI-visible cortical lesions. J. Neurol. 259, 2695–2698 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22714135</ArticleId><ArticleId IdType="doi">10.1007/s00415-012-6571-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Daams, M., Geurts, J. J. &amp; Barkhof, F. Cortical imaging in multiple sclerosis: recent findings and ‘grand challenges’. Curr. Opin. Neurol. 26, 345–352 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23812306</ArticleId><ArticleId IdType="doi">10.1097/WCO.0b013e328362a864</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocca, M. A. et al. Long-term disability progression in primary progressive multiple sclerosis: a 15-year study. Brain 140, 2814–2819 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29053836</ArticleId><ArticleId IdType="doi">10.1093/brain/awx250</ArticleId></ArticleIdList></Reference><Reference><Citation>Filippi, M., Preziosa, P. &amp; Rocca, M. A. Magnetic resonance outcome measures in multiple sclerosis trials: time to rethink? Curr. Opin. Neurol. 27, 290–299 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24792339</ArticleId><ArticleId IdType="doi">10.1097/WCO.0000000000000095</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojano, M. et al. Treatment decisions in multiple sclerosis — insights from real-world observational studies. Nat. Rev. Neurol. 13, 105–118 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28084327</ArticleId><ArticleId IdType="doi">10.1038/nrneurol.2016.188</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalincik, T. et al. Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. Brain 140, 2426–2443 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29050389</ArticleId><ArticleId IdType="doi">10.1093/brain/awx185</ArticleId></ArticleIdList></Reference><Reference><Citation>Havrdova, E. et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the natalizumab safety and efficacy in relapsing-remitting multiple sclerosis (AFFIRM) study. Lancet Neurol. 8, 254–260 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19201654</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(09)70021-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovannoni, G., Tomic, D., Bright, J. R. &amp; Havrdová, E. “No evident disease activity”: the use of combined assessments in the management of patients with multiple sclerosis. Mult. Scler. 23, 1179–1187 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28381105</ArticleId><ArticleId IdType="pmcid">5536258</ArticleId><ArticleId IdType="doi">10.1177/1352458517703193</ArticleId></ArticleIdList></Reference><Reference><Citation>Parks, N. E., Flanagan, E. P., Lucchinetti, C. F. &amp; Wingerchuk, D. M. NEDA treatment target? No evident disease activity as an actionable outcome in practice. J. Neurol. Sci. 383, 31–34 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29246616</ArticleId><ArticleId IdType="doi">10.1016/j.jns.2017.10.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotstein, D. L., Healy, B. C., Malik, M. T., Chitnis, T. &amp; Weiner, H. L. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol. 72, 152–158 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25531931</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2014.3537</ArticleId></ArticleIdList></Reference><Reference><Citation>De Stefano, N. et al. Long-term assessment of no evidence of disease activity in relapsing-remitting MS. Neurology 85, 1722–1723 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26468405</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000002105</ArticleId></ArticleIdList></Reference><Reference><Citation>Damasceno, A., Damasceno, B. P. &amp; Cendes, F. No evidence of disease activity in multiple sclerosis: implications on cognition and brain atrophy. Mult. Scler. 22, 64–72 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26432855</ArticleId><ArticleId IdType="doi">10.1177/1352458515604383</ArticleId></ArticleIdList></Reference><Reference><Citation>Stangel, M., Penner, I. K., Kallmann, B. A., Lukas, C. &amp; Kieseier, B. C. Towards the implementation of ‘no evidence of disease activity’ in multiple sclerosis treatment: the multiple sclerosis decision model. Ther. Adv. Neurol. Disord. 8, 3–13 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25584069</ArticleId><ArticleId IdType="pmcid">4286940</ArticleId><ArticleId IdType="doi">10.1177/1756285614560733</ArticleId></ArticleIdList></Reference><Reference><Citation>Kappos, L. et al. Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing-remitting multiple sclerosis. Mult. Scler. 22, 1297–1305 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26585439</ArticleId><ArticleId IdType="doi">10.1177/1352458515616701</ArticleId></ArticleIdList></Reference><Reference><Citation>Marrie, R. A. &amp; Horwitz, R. I. Emerging effects of comorbidities on multiple sclerosis. Lancet Neurol. 9, 820–828 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20650403</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(10)70135-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Marrie, R. A. Comorbidity in multiple sclerosis: implications for patient care. Nat. Rev. Neurol. 13, 375–382 (2017). This paper provides an extensive summary of the prevalence of comorbidity in MS and a discussion of the effects of comorbidity on clinically relevant outcomes in MS and of the potential implications for treatment.</Citation><ArticleIdList><ArticleId IdType="pubmed">28303911</ArticleId><ArticleId IdType="doi">10.1038/nrneurol.2017.33</ArticleId></ArticleIdList></Reference><Reference><Citation>Marrie, R. A. et al. Recommendations for observational studies of comorbidity in multiple sclerosis. Neurology 86, 1446–1453 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26865523</ArticleId><ArticleId IdType="pmcid">4831039</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000002474</ArticleId></ArticleIdList></Reference><Reference><Citation>Marrie, R. A. et al. The challenge of comorbidity in clinical trials for multiple sclerosis. Neurology 86, 1437–1445 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26888986</ArticleId><ArticleId IdType="pmcid">4831041</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000002471</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, T. et al. Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis. Neurology 86, 1287–1295 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26944268</ArticleId><ArticleId IdType="pmcid">4826339</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000002543</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao, Y. et al. Functional inflammatory profiles distinguish myelin-reactive T cells from patients with multiple sclerosis. Sci. Transl Med. 7, 287ra74 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25972006</ArticleId><ArticleId IdType="pmcid">4497538</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aaa8038</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhaunchak, A. S. et al. Implication of perturbed axoglial apparatus in early pediatric multiple sclerosis. Ann. Neurol. 71, 601–613 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22473675</ArticleId><ArticleId IdType="doi">10.1002/ana.22693</ArticleId></ArticleIdList></Reference><Reference><Citation>Ascherio, A. &amp; Munger, K. L. Epidemiology of multiple sclerosis: from risk factors to prevention — an update. Semin. Neurol. 36, 103–114 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27116717</ArticleId><ArticleId IdType="doi">10.1055/s-0036-1579693</ArticleId></ArticleIdList></Reference><Reference><Citation>Yea, C. et al. Epstein-Barr virus in oral shedding of children with multiple sclerosis. Neurology 81, 1392–1399 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24014504</ArticleId><ArticleId IdType="pmcid">3806908</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e3182a841e4</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunemann, J. D. et al. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. J. Exp. Med. 205, 1763–1773 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18663124</ArticleId><ArticleId IdType="pmcid">2525578</ArticleId><ArticleId IdType="doi">10.1084/jem.20072397</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunemann, J. D. et al. Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Ann. Neurol. 67, 159–169 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20225269</ArticleId><ArticleId IdType="pmcid">2848293</ArticleId><ArticleId IdType="doi">10.1002/ana.21886</ArticleId></ArticleIdList></Reference><Reference><Citation>Angelini, D. F. et al. Increased CD8<sup>+</sup> T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis. PLOS Pathog. 9, e1003220 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23592979</ArticleId><ArticleId IdType="pmcid">3623710</ArticleId><ArticleId IdType="doi">10.1371/journal.ppat.1003220</ArticleId></ArticleIdList></Reference><Reference><Citation>Quintana, F. J. et al. Epitope spreading as an early pathogenic event in pediatric multiple sclerosis. Neurology 83, 2219–2226 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25381299</ArticleId><ArticleId IdType="pmcid">4277672</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000001066</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed, R. M. et al. A practical approach to diagnosing adult onset leukodystrophies. J. Neurol. Neurosurg. Psychiatry 85, 770–781 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24357685</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2013-305888</ArticleId></ArticleIdList></Reference><Reference><Citation>Chun, B. Y. &amp; Rizzo, J. F. 3rd Dominant optic atrophy and Leber’s hereditary optic neuropathy: update on clinical features and current therapeutic approaches. Semin. Pediatr. Neurol. 24, 129–134 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28941528</ArticleId><ArticleId IdType="doi">10.1016/j.spen.2017.06.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar, N., Ahlskog, J. E., Klein, C. J. &amp; Port, J. D. Imaging features of copper deficiency myelopathy: a study of 25 cases. Neuroradiology 48, 78–83 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16261334</ArticleId><ArticleId IdType="doi">10.1007/s00234-005-0016-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Chabriat, H., Joutel, A., Dichgans, M., Tournier-Lasserve, E. &amp; Bousser, M. G. Cadasil. Lancet Neurol. 8, 643–653 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19539236</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(09)70127-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Wingerchuk, D. M. et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85, 177–189 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">4515040</ArticleId><ArticleId IdType="pmcid">4515040</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000001729</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarius, S. et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J. Neuroinflamm. 15, 134 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-018-1144-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenembaum, S., Chitnis, T., Ness, J. &amp; Hahn, J. S. Acute disseminated encephalomyelitis. Neurology 68, S23–S36 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17438235</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000259404.51352.7f</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobin, W. O. et al. Diagnostic criteria for chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). Brain 140, 2415–2425 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29050399</ArticleId><ArticleId IdType="doi">10.1093/brain/awx200</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon, J. H. &amp; Kleinschmidt-DeMasters, B. K. Variants of multiple sclerosis. Neuroimaging Clin. N. Am. 18, 703–716 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">19068410</ArticleId><ArticleId IdType="doi">10.1016/j.nic.2008.06.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Lublin, F. D. &amp; Reingold, S. C. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 46, 907–911 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8780061</ArticleId><ArticleId IdType="doi">10.1212/WNL.46.4.907</ArticleId></ArticleIdList></Reference><Reference><Citation>McAlpine, D. Multiple sclerosis: a review. BMJ 2, 292–295 (1973).</Citation><ArticleIdList><ArticleId IdType="pubmed">4574348</ArticleId><ArticleId IdType="doi">10.1136/bmj.2.5861.292</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald, W. I. Relapse, remission, and progression in multiple sclerosis. N. Engl. J. Med. 343, 1486–1487 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11078776</ArticleId><ArticleId IdType="doi">10.1056/NEJM200011163432010</ArticleId></ArticleIdList></Reference><Reference><Citation>Patzold, U. &amp; Pocklington, P. R. Course of multiple sclerosis: first results of a prospective study carried out of 102 MS patients from 1976–1980. Acta Neurol. Scand. 65, 248–266 (1982).</Citation><ArticleIdList><ArticleId IdType="pubmed">7102254</ArticleId><ArticleId IdType="doi">10.1111/j.1600-0404.1982.tb03084.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Pauli, F. et al. Smoking is a risk factor for early conversion to clinically definite multiple sclerosis. Mult. Scler. 14, 1026–1030 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18632775</ArticleId><ArticleId IdType="doi">10.1177/1352458508093679</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinelli, V. et al. Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes. Mult. Scler. 20, 147–155 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">23836877</ArticleId><ArticleId IdType="doi">10.1177/1352458513494959</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianfrancesco, M. A. et al. Obesity during childhood and adolescence increases susceptibility to multiple sclerosis after accounting for established genetic and environmental risk factors. Obes. Res. Clin. Pract. 8, e435–e447 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25263833</ArticleId><ArticleId IdType="pmcid">4180039</ArticleId><ArticleId IdType="doi">10.1016/j.orcp.2014.01.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedstrom, A. K., Olsson, T. &amp; Alfredsson, L. High body mass index before age 20 is associated with increased risk for multiple sclerosis in both men and women. Mult. Scler. 18, 1334–1336 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22328681</ArticleId><ArticleId IdType="doi">10.1177/1352458512436596</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jager, P. L. et al. Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score. Lancet Neurol. 8, 1111–1119 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19879194</ArticleId><ArticleId IdType="pmcid">3099419</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(09)70275-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly, M. A. et al. The influence of HLA-DR and -DQ alleles on progression to multiple sclerosis following a clinically isolated syndrome. Hum. Immunol. 37, 185–191 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8244781</ArticleId><ArticleId IdType="doi">10.1016/0198-8859(93)90184-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Mowry, E. M. et al. Clinical predictors of early second event in patients with clinically isolated syndrome. J. Neurol. 256, 1061–1066 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19252775</ArticleId><ArticleId IdType="pmcid">2708331</ArticleId><ArticleId IdType="doi">10.1007/s00415-009-5063-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidhom, Y. et al. Fast multiple sclerosis progression in North Africans: both genetics and environment matter. Neurology 88, 1218–1225 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28235811</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000003762</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobson, R., Ramagopalan, S. &amp; Giovannoni, G. The effect of gender in clinically isolated syndrome (CIS): a meta-analysis. Mult. Scler. 18, 600–604 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">21993498</ArticleId><ArticleId IdType="doi">10.1177/1352458511426740</ArticleId></ArticleIdList></Reference><Reference><Citation>Confavreux, C., Vukusic, S. &amp; Adeleine, P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126, 770–782 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12615637</ArticleId><ArticleId IdType="pmcid">12615637</ArticleId><ArticleId IdType="doi">10.1093/brain/awg081</ArticleId></ArticleIdList></Reference><Reference><Citation>Bove, R. M. et al. Effect of gender on late-onset multiple sclerosis. Mult. Scler. 18, 1472–1479 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22383227</ArticleId><ArticleId IdType="doi">10.1177/1352458512438236</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillemin, F. et al. Older age at multiple sclerosis onset is an independent factor of poor prognosis: a population-based cohort study. Neuroepidemiology 48, 179–187 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28793296</ArticleId><ArticleId IdType="doi">10.1159/000479516</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson, M., Andersen, O. &amp; Runmarker, B. Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis. Mult. Scler. 9, 260–274 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12814173</ArticleId><ArticleId IdType="doi">10.1191/1352458503ms914oa</ArticleId></ArticleIdList></Reference><Reference><Citation>Tintore, M. et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain 138, 1863–1874 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25902415</ArticleId><ArticleId IdType="doi">10.1093/brain/awv105</ArticleId></ArticleIdList></Reference><Reference><Citation>Comi, G. et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357, 1576–1582 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11377645</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(00)04725-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen, J. M. et al. MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome. BMC Neurol. 9, 19 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19457248</ArticleId><ArticleId IdType="pmcid">2702360</ArticleId><ArticleId IdType="doi">10.1186/1471-2377-9-19</ArticleId></ArticleIdList></Reference><Reference><Citation>Scalfari, A. et al. The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability. Brain 133, 1914–1929 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20534650</ArticleId><ArticleId IdType="pmcid">2892939</ArticleId><ArticleId IdType="doi">10.1093/brain/awq118</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez, M. A. et al. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. Mult. Scler. 21, 550–561 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25732842</ArticleId><ArticleId IdType="pmcid">4390605</ArticleId><ArticleId IdType="doi">10.1177/1352458514549397</ArticleId></ArticleIdList></Reference><Reference><Citation>Minneboo, A. et al. Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis. Arch. Neurol. 61, 217–221 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14967769</ArticleId><ArticleId IdType="doi">10.1001/archneur.61.2.217</ArticleId></ArticleIdList></Reference><Reference><Citation>Tintore, M. et al. Brainstem lesions in clinically isolated syndromes. Neurology 75, 1933–1938 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">21098409</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e3181feb26f</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrambide, G. et al. Spinal cord lesions: a modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor. Mult. Scler. 24, 301–312 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28301287</ArticleId><ArticleId IdType="doi">10.1177/1352458517697830</ArticleId></ArticleIdList></Reference><Reference><Citation>Sombekke, M. H. et al. Spinal cord lesions in patients with clinically isolated syndrome: a powerful tool in diagnosis and prognosis. Neurology 80, 69–75 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23243070</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e31827b1a67</ArticleId></ArticleIdList></Reference><Reference><Citation>Brownlee, W. J. et al. Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome. Mult. Scler. 23, 665–674 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27481210</ArticleId><ArticleId IdType="doi">10.1177/1352458516663034</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson, K. P. et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 45, 1268–1276 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7617181</ArticleId><ArticleId IdType="doi">10.1212/WNL.45.7.1268</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebers, G. C. &amp; PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 352, 1498–1504 (1998).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(98)03334-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs, L. D. et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann. Neurol. 39, 285–294 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8602746</ArticleId><ArticleId IdType="doi">10.1002/ana.410390304</ArticleId></ArticleIdList></Reference><Reference><Citation>The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 43, 655–661 (1993).</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.43.4.655</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabresi, P. A. et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 13, 657–665 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24794721</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(14)70068-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Confavreux, C. et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 13, 247–256 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24461574</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(13)70308-9</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Connor, P. et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N. Engl. J. Med. 365, 1293–1303 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21991951</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1014656</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox, R. J. et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N. Engl. J. Med. 367, 1087–1097 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22992072</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1206328</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold, R. et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N. Engl. J. Med. 367, 1098–1107 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22992073</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1114287</ArticleId></ArticleIdList></Reference><Reference><Citation>Kappos, L. et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362, 387–401 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20089952</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa0909494</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabresi, P. A. et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 13, 545–556 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24685276</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(14)70049-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Kappos, L. et al. Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. N. Engl. J. Med. 373, 1418–1428 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26444729</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1501481</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen, J. A. et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380, 1819–1828 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23122652</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(12)61769-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Coles, A. J. et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380, 1829–1839 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23122650</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(12)61768-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovannoni, G. et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N. Engl. J. Med. 362, 416–426 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20089960</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa0902533</ArticleId></ArticleIdList></Reference><Reference><Citation>Polman, C. H. et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354, 899–910 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16510744</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa044397</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudick, R. A. et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N. Engl. J. Med. 354, 911–923 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16510745</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa044396</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>